As demand rises for precision-engineered components in advanced therapeutic applications, ProMed is setting a higher bar for quality and performance in medical device silicone molding.
-- As demand rises for precision-engineered components in advanced therapeutic applications, ProMed is setting a higher bar for quality and performance in medical device silicone molding. With more than three decades of experience serving regulated industries, the company is expanding its capabilities to better support the next wave of innovation in medical, pharmaceutical, and combination device development.
Known for its work in short- and long-term implantable devices, drug-releasing technologies, and customized molding solutions, ProMed continues to invest in materials expertise, in-house tooling, and highly controlled manufacturing environments. The company’s commitment to meeting the evolving needs of OEMs and startups alike has positioned it as a trusted partner for some of the most complex and compliance-driven molding projects in healthcare.
Recent advancements at ProMed include the integration of enhanced automation systems, expanded capacity in Class 7 cleanroom environments, and new process controls aimed at supporting tighter tolerances and greater consistency across high-volume runs. These developments not only reduce time to market but also improve scalability for customers preparing to launch novel therapies and drug-device combinations.
At the core of ProMed’s value is its ability to manage silicone molding projects from prototype through production, providing engineering support, tool design, material selection, and manufacturing under one roof. The company’s development center in Plymouth, MN, plays a key role in accelerating design for manufacturability (DFM) efforts while maintaining traceability and quality across all stages of production.
ProMed’s deep understanding of elastomeric materials—including both Liquid Silicone Rubber (LSR) and High Consistency Rubber (HCR)—remains essential in creating devices that demand chemical stability, biocompatibility, and performance under dynamic biological conditions. With durometer ranges from 10 to 80 Shore A and shot size capabilities from 0.5ccm to 180ccm, the company is equipped to support a broad spectrum of device types, from micro-molded drug delivery implants to larger over-molded surgical components.
In the realm of medical device silicone molding, precision is not just a technical requirement—it’s a regulatory imperative. ProMed maintains ISO 13485 certification, FDA registration, and ITAR compliance, ensuring that all products meet or exceed quality management expectations. Cross-functional teams of engineers, quality professionals, and manufacturing specialists collaborate closely to preserve dimensional stability and material integrity throughout the product lifecycle.
This approach has been especially valuable in supporting combination devices, which require seamless integration of pharmaceutical ingredients with device substrates. ProMed offers specialized expertise in achieving desired drug release profiles using silicone as a controlled-release medium, helping to bridge the gap between traditional device design and pharmaceutical efficacy. The company’s pharma-dedicated facility in Maple Grove, MN, and expanded operations in Dorado, Puerto Rico, further strengthen these capabilities.
In addition to its technical capabilities, ProMed remains committed to sustainable manufacturing practices. Strategic use of materials, waste reduction initiatives, and supply chain reliability are built into each program, offering long-term value to partners navigating complex markets and tight regulatory windows.
As innovation in MedTech and pharma continues to accelerate, ProMed’s tailored approach to silicone molding stands out. Whether supporting a startup's first prototype or helping a global OEM scale up production for a new therapy, the company delivers consistency, reliability, and deep industry insight. With a structured organization designed to handle critical projects from concept to completion, ProMed remains focused on one goal: enabling the future of healthcare through smart, scalable, and compliant silicone molding solutions.
About ProMed:
Since 1989 ProMed has been recognized as a leading Contract Manufacturer of complex, intricately designed molded silicone and plastic components and assemblies for highly regulated industries. ProMed’s expertise extends across applications for short-term and long-term implantable devices, drug-releasing combination devices, and specialized materials and processes for aerospace, defense, and automotive applications. We collaboratively work with our customers from prototype through production, providing over 30 years of experience related to design for manufacturability, material selection, tool and fixture design, process development, manufacturing, and other value-added services that result in cost-effective solutions with superior quality.
About the company: Since 1989 ProMed has been recognized as a leading Contract Manufacturer of complex, intricately designed molded silicone and plastic components and assemblies for highly regulated industries. ProMed’s expertise extends across applications for short-term and long-term implantable devices, drug-releasing combination devices, and specialized materials and processes for aerospace, defense, and automotive applications.
Contact Info:
Name: Kevin Roy
Email: Send Email
Organization: GreenBanana
Website: http://www.greenbananaseo.com
Release ID: 89163203
Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.
